British drugmaker GSK (GSK.L) said on Tuesday its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology (VIR.O) is effective against all mutations of the new Omicron coronavirus variant. In fact, the companies’ treatment, sotrovimab,injection, 500 mg, for intravenous use, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement. Sotrovimab is designed to latch on to the spike protein on the surface of the coronavirus. At this time, Sotrovimab is temporarily authorized by FDA for use under an Emergency Use Authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Patients treated with sotrovimab should continue to self-isolate and use infection control measures (eg, wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to CDC guidelines. There are however limitations. Sotrovimab is not authorized for use in patients who require oxygen therapy due to COVID-19. Some adverse reactions to Sotrovimab were obseved: serious hypersensitivity reactions, including anaphylaxis and signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status.